Idorsia Ltd (IDIA) - Cash Flow Conversion Efficiency

Latest as of March 2026: 0.023x

Based on the latest financial reports, Idorsia Ltd (IDIA) has a cash flow conversion efficiency ratio of 0.023x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF-26.63 Million ≈ $-33.67 Million USD) by net assets (CHF-1.18 Billion ≈ $-1.49 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Idorsia Ltd fund operations to measure how many days the company can operate on defensive assets alone.

Idorsia Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how Idorsia Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Idorsia Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Idorsia Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Neway CNC Equipment Suzhou Co Ltd
SHG:688697
0.043x
Guangdong Shaoneng Group Co Ltd
SHE:000601
0.095x
ChemoMetec A/S
CO:CHEMM
0.139x
CEVA Inc
NASDAQ:CEVA
0.026x
Jiangsu Canlon Building Materials Co Ltd
SHE:300715
0.003x
Empresas Lipigas S.A.
SN:LIPIGAS
0.261x
Accel Entertainment Inc
NYSE:ACEL
0.155x
Inversiones Aguas Metropolitanas SA
SN:IAM
0.039x

Annual Cash Flow Conversion Efficiency for Idorsia Ltd (2016–2025)

The table below shows the annual cash flow conversion efficiency of Idorsia Ltd from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Idorsia Ltd.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 CHF-1.14 Billion
≈ $-1.44 Billion
CHF-153.23 Million
≈ $-193.72 Million
0.135x -55.88%
2024-12-31 CHF-1.21 Billion
≈ $-1.53 Billion
CHF-370.23 Million
≈ $-468.07 Million
0.305x -52.98%
2023-12-31 CHF-968.72 Million
≈ $-1.22 Billion
CHF-629.30 Million
≈ $-795.60 Million
0.650x -50.02%
2022-12-31 CHF-660.96 Million
≈ $-835.63 Million
CHF-859.11 Million
≈ $-1.09 Billion
1.300x +122.96%
2021-12-31 CHF104.20 Million
≈ $131.74 Million
CHF-589.89 Million
≈ $-745.79 Million
-5.661x -808.88%
2020-12-31 CHF585.48 Million
≈ $740.21 Million
CHF-364.67 Million
≈ $-461.04 Million
-0.623x +77.85%
2019-12-31 CHF164.35 Million
≈ $207.78 Million
CHF-462.04 Million
≈ $-584.14 Million
-2.811x -424.02%
2018-12-31 CHF657.62 Million
≈ $831.42 Million
CHF-352.82 Million
≈ $-446.06 Million
-0.537x -515.46%
2017-12-31 CHF739.51 Million
≈ $934.94 Million
CHF95.50 Million
≈ $120.73 Million
0.129x +124.91%
2016-12-31 CHF507.97 Million
≈ $642.21 Million
CHF-263.34 Million
≈ $-332.93 Million
-0.518x --

About Idorsia Ltd

SW:IDIA Switzerland Biotechnology
Market Cap
$1.88 Billion
CHF1.48 Billion CHF
Market Cap Rank
#8955 Global
#119 in Switzerland
Share Price
CHF5.85
Change (1 day)
+25.70%
52-Week Range
CHF1.87 - CHF5.85
All Time High
CHF33.62
About

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the… Read more